Welcome to our dedicated page for TRINITY BIOTECH PLC SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trinity Biotech plc SEC filings document foreign-issuer reports furnished on Form 6-K for its diagnostics, diabetes management, and health technology operations. The filings record announcements tied to Premier Hb9210 diabetes testing, CGM+ biosensor development, EpiCapture prostate cancer diagnostics, North America commercial operations, trading updates, and the Comprehensive Transformation Plan.
The company’s filings also disclose ADS and ordinary-share capital matters, including a standby equity purchase agreement; credit-agreement waivers and covenant deferrals; Nasdaq listing-compliance notices for the ADSs; and incorporation by reference into Form S-8 registration statements. These records describe the formal reporting framework for Trinity Biotech as a foreign private issuer using Form 20-F reporting status.
Trinity Biotech plc filed a Form 6-K to report that, on November 18, 2025, it issued a press release announcing a major regulatory approval related to manufacturing of its Uni-Gold rapid HIV test. The approval covers offshored and outsourced production of this market-leading diagnostic product.
The company describes this step as part of a broader effort to transform its financial performance, suggesting that the new manufacturing structure is intended to support that strategy. Details of the approval and its expected impact are contained in the press release attached as Exhibit 99.1.
Trinity Biotech plc submitted a Form 6-K to report a corporate update related to its EpiCapture prostate cancer testing technology. The company states that on November 14, 2025 it issued a press release announcing a collaboration to advance epigenetic analysis for its EpiCapture prostate cancer test, and has attached that release as Exhibit 99.1. The filing also notes that this report is incorporated by reference into Trinity Biotech’s existing registration statements on Form S-8.
Trinity Biotech plc filed a Form 6-K announcing two administrative updates. Shareholders approved amendments to the Company’s Constitution at the Annual General Meeting held on September 30, 2025. The Company and certain subsidiaries also executed an amendment to the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P.
The amended Constitution is filed as Exhibit 99.1, and the First Amendment to the Sixth Amended and Restated Credit Agreement and Guaranty, dated October 16, 2025, is filed as Exhibit 99.2. This Form 6-K is incorporated by reference into the Company’s existing Form S-8 registration statements.
Trinity Biotech plc reports that shareholders approved all resolutions put forward at its annual general meeting held on September 30, 2025, each passing with at least 93% of votes cast. This indicates very strong support for the proposals presented to investors.
The company also notes that Jim Walsh retired by rotation from the board of directors in line with the company’s constitution, after more than 30 years of service. Trinity Biotech expresses its gratitude for his long-standing contributions and explains that he will continue to support the company’s management team in a new capacity as a Scientific Advisor.
Trinity Biotech plc submitted a routine update that makes its full Annual Report 2024 available to investors. The company is also distributing key materials for its upcoming annual general meeting to holders of its ordinary shares.
The documents provided include the 2024 annual report, a letter from the company secretary, the formal notice of the annual general meeting, and a proxy card that allows shareholders to vote by proxy. These materials are intended to help shareholders review the company’s performance over the past year and participate in governance decisions at the meeting.
Trinity Biotech plc filed a Form 6-K to report that, as of September 2, 2025, it has regained compliance with Nasdaq Listing Requirements. This means the company once again meets the standards needed for its shares to remain listed on the Nasdaq market. The filing notes that this update was first announced in a press release, which is included as Exhibit 99.1. The document is also incorporated by reference into Trinity Biotech’s existing employee share plan registration statements on Form S-8.
Trinity Biotech plc filed a Form 6-K to furnish a press release announcing that it received regulatory approval to begin offshored and outsourced manufacturing of its flagship rapid HIV test. The company describes this step as supporting both strategic change and improved financial performance.
Trinity Biotech plc filed a report noting that it has received regulatory approval to begin offering its FDA-cleared PreClara™ preeclampsia testing service. This approval allows the company to start providing a diagnostic testing service aimed at detecting preeclampsia, a serious pregnancy-related condition. The company communicated this development through a press release dated August 14, 2025, which is attached as an exhibit to the report.
Trinity Biotech reported breakthrough clinical trial results for its redesigned continuous glucose monitoring (CGM) sensor, indicating a significant development in its product pipeline. The Form 6-K states the company issued a press release describing those trial results and filed it as Exhibit 99.1. The filing also discloses that on August 7, 2025 the company and certain subsidiaries amended and restated the credit agreement governing their term loan facility with Perceptive Credit Holdings III, L.P. and that a warrant to purchase American Depositary Shares was issued in connection with that agreement. Copies of the press release, the Sixth Amended and Restated Credit Agreement and the warrant certificate are included as Exhibits 99.1, 99.2 and 99.3.
Trinity Biotech plc notified investors via Form 6-K that it issued a press release announcing the launch of an FDA-cleared Preeclampsia Testing Service. The company filed that press release as Exhibit 99.1 to the Form 6-K and stated the report is being incorporated by reference into its Form S-8 registration statements. The filing is signed by Chief Executive Officer John Gillard. The Form contains no financial results, pricing, partner or rollout details, and provides no operational or revenue metrics for the new service.